Brief: Merck Enters Exclusive Global License Deal With Scibrunch Therapeutics For SPR2015
28/09/2026 12:07
BRIEF-Merck Enters Exclusive Global License Deal With Scibrunch Therapeutics For SPR2015 Sept 28 (Reuters) - Merck & Co Inc MRK.N:
SAYS MERCK ENTERS EXCLUSIVE GLOBAL LICENSE DEAL WITH SCIBRUNCH THERAPEUTICS FOR INVESTIGATIONAL ORAL KRAS G12D (ON) INHIBITOR SPR2015
Further company coverage: MRK.N
(Reporting by Beijing Newsroom)
Recent news on Merck & Co
See all newsModerna sheds about $24 billion as cancer vaccine data triggers 'sell-the-news' retreat
Merck/Moderna cancer vaccine cuts melanoma death or recurrence risk by 42%, shares fall (updated)
Brief: Merck Says Intismeran Plus Keytruda Significantly Reduced Risk Of Recurrence Or Death By 42%
Merck/Moderna cancer vaccine cuts risk of death or recurrence from melanoma by over 40%
Moderna falls as social media posts flag potential cancer vaccine data leak